KDA Group Inc.

Equities

KDA

CA48669F1071

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:35:08 2024-07-11 pm EDT			5-day change	1st Jan Change
0.2925 ^CAD	+0.86%		+8.33%	+46.25%

Jun. 21	KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
Jun. 12	KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer	CI

KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2021

December 17, 2021 at 05:14 pm EST

KDA Group Inc. reported earnings results for the first quarter ended October 31, 2021. For the first quarter, the company reported sales was CAD 5.54 million compared to CAD 5.32 million a year ago. Net loss was CAD 1.99 million compared to CAD 0.104649 million a year ago. Basic loss per share was CAD 0.01.

Latest news about KDA Group Inc.

KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	Jun. 20	CI
KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer	Jun. 12	CI
KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 28	CI
KDA Group Inc. Announces an Update in the Development and Use of Its Adherize+ Platform	Mar. 21	CI
KDA Group Inc. Announces the Appointments of Yves Marmet as General Manager and Chief Technology Officer and Marie-Hélène Pinard as Chief Operating Officer of Groupe Technologique KDA Inc	Feb. 22	CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 19	CI
ZoomMed Announced Distribution to Its Shareholders of 5 Million Common Shares It Holds in KDA Group	Dec. 18	MT
KDA Group Inc. announced that it has received CAD 1.125 million in funding	Dec. 07	CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 27	CI
KDA Group Inc. Announces Executive Changes	23-09-05	CI
KDA Group Inc. acquired Substantially all the assets in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.	23-07-27	CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-07-06	CI
KDA Group Inc. Announces Directors Resignation	23-06-29	CI
9486-4410 Quebec Inc completed the acquisition of Agence L.I.V. Inc. from KDA Group Inc..	23-06-27	CI
ZoomMed Board Ratifies Asset Sale to KDA Group	23-06-27	MT
KDA Group Inc. entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.	23-06-26	CI
9486-4410 Quebec Inc entered into a share purchase agreement to acquire Agence L.I.V. Inc. from KDA Group Inc. for $13.5 million.	23-05-28	CI
Halsa Health Group Inc. entered into a share purchase agreement to acquire Élitis Pharma Inc. and Logistique Pharma Inc. from KDA Group Inc. for $2.1 million.	23-03-26	CI
KDA Group Inc. acquired Covapharm Inc for CAD 0.38 million.	22-12-20	CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-14	CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-11-25	CI
KDA Group Inc. Auditor Raises 'Going Concern' Doubt	22-11-24	CI
KDA Group Inc. Appoints Luc Olivier as Chief Financial Officer	22-10-18	CI
KDA Group Inc. Announces Executive Changes	22-07-29	CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	22-06-23	CI

Chart KDA Group Inc.

Duration

Period

More charts

Company Profile

KDA Group Inc. is a Canada-based solution and services provider to pharmacies and pharmaceutical companies in Canada as well as technological platform for the health industry. The Companyâs segments include Pharmacy Services, Pharmaceutical Solutions and Pharmaceutical Technology. Its Pharmacy Services segment offers training, consulting, and replacement services for professional resources in the field of healthcare. Its Pharmaceutical Solutions segment is engaged in the development and integration of technological platforms dedicated to all healthcare professionals. Its Pharmaceutical technology segment offers KRX, KRX DENTAL and ADRX platforms. It also offers ZRx Digital Prescriber an electronic prescriber computer and mobile software designed and developed for use by healthcare providers who are authorized to prescribe medications and other treatments. Its subsidiaries include Alliance Pharma Operations Inc., Elitis Pharma Inc., Logistik Pharma Inc. and Groupe Technologique KDA Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-11-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KDA GROUP INC.	+46.25%	37.68M
MODERNA, INC.	+23.50%	47.07B
LONZA GROUP AG	+47.19%	42.06B
IQVIA HOLDINGS INC.	-5.16%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+36.37%	33.02B
CELLTRION, INC.	-7.79%	27.9B
ICON PUBLIC LIMITED COMPANY	+18.06%	27.63B
UNITED THERAPEUTICS CORPORATION	+47.29%	14.37B
MEDPACE HOLDINGS, INC.	+41.91%	13.45B
BIO-TECHNE CORPORATION	-1.02%	12.03B

Other Biotechnology & Medical Research